ArticleBMC cancer2025
Anti-cancer properties of chitosan /Lactobacillus acidophilus secretome nanoparticle on signaling pathways of colorectal cancer in colon adenocarcinoma (Caco-2) cell line.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gastrointestinal Microbiome Dysbiosis in Cancer Development: Mechanisms and Biomarker Potential.MicrobiologyOpen · 2026Review
- Cell secretome as a potential anticancer therapeutic agent: composition, mechanisms, preclinical evidence, and translational challenges.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) has emerged as a global health concern, as evidenced by its position as the second leading cause of cancer-related mortality. This underscores the necessity for effective disease management strategies. The present study aims to assess the impact of chitosan nanoparticles (CSNP) conjugated with the Lactobacillus acidophilus secretome (CSNP/L.a-sup), on the signaling pathways associated with CRC.
methodsThe CSNP/L.a-sup was prepared using an ionic gelation procedure, and its particle size, surface charge, and morphology were evaluated using dynamic light scattering, zeta potential, and scanning electron microscopy. The encapsulation efficiency (EE) and the protein released from CSNP/L.a-sup were assayed using a BCA assay kit. CSNP/L.a-sup toxicity on colon adenocarcinoma (Caco-2) and human dermal fibroblasts (HDF) cells was assessed via the MTT assay. The expression levels of CRC signaling pathway genes were examined using real-time polymerase chain reaction (PCR).
resultsThe size of CSNP/L.a-sup was detected at 478.6 ± 219.9 nm, with a surface charge of -8.9 mV. The protein released from CSNP/L.a-sup was observed 76% at pH ~ 6.8 after 48 h, with EE of 74.6%. The viability of Caco-2 and HDF cells against CSNP/L.a-sup was found to be 85.5% and 92.6%, respectively. The uptake of CSNP/L.a-sup by Caco-2 cells occurs in a time-dependent manner, with initial absorption observed within 1 h and substantial internalization achieved after 3 h. CSNP/L.a-sup led to a significant decrease in the expression of β-Catenin, TGF-α, and TGF-β genes, with respective changes of 0.42, 0.79, and 0.16-fold. In contrast, CSNP/L.a-sup led to a significant increase in the expression of PTEN and caspase-9 suppressor genes, with changes of 42.1 and 114.3-fold, respectively. The inhibitory effect of CSNP/L.a-sup on TGF-α gene expression appears to be more closely associated with the CSNP compartment, while the enhancing effect of CSNP/L.a-sup on PTEN gene expression is linked to L.a-sup.
conclusionThis investigation signifies an inaugural exploration into the potential of a combination therapy comprising secretome of probiotic bacteria and chitosan nanostructures. This approach constitutes a substantial advancement in the field of developing efficacious treatment strategies, offering novel insights into the management of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.